

# Pfizer Research Grant Request for Proposals

Competitive Grant Program – using Expert Review Panel

## *Real-World Atopic Dermatitis: Italian Insights Grant*



### Overview

Pfizer is launching a competitive grant program to support Investigator's Sponsored Research (ISR) projects aimed at collecting real-world data (RWD) emerging from the on-label abrocitinib (200 mg and 100 mg) indication to adult patients ( $\geq 18$  years) with Atopic Dermatitis (AD) in the Italian clinical practice.

The intent of this RFP is to encourage proposals that align with current therapeutic guidelines (1) and address unmet needs in the Italian clinical scenario (2, 3, 4).



### Geographic Scope

Italy



### Project Types and Area of Interest

Applicants are encouraged to submit projects aimed at generating real-world evidence (RWE) to address current gaps in the management of AD in Italy, with a specific focus on abrocitinib, to further investigate its effectiveness and safety.



### Key Milestones

**Submission Deadline**

**Anticipated Grant Award Notification**

**Anticipated Project Start Date**



19 FEB 2026

31 MAR 2026

BY 30 JUN 2026



### Funding Range and Project Length

- Individual projects requesting up to 50.000,00 Eur will be considered. The estimated total available budget related to this RFP is 200.000,00 Eur.
- Projects should last no longer than 12 months.

## I. Eligibility

---

### Geographic Scope:

- Italy

### Applicant Eligibility Criteria

- The institution and Principal Investigator (PI) must be based in Italy.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project. Collaborations within Institutions (e.g., between departments), as well as between different Institutions/Organizations, are encouraged.
- The PI must have a medical or doctoral degree (MD, PhD, or equivalent)
- The applicant must be the PI or an authorized designee of such individual (e.g., PI's research coordinator).
- The PI must be an employee of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer International LLC. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer International LLC may be subject to rescission.

## II. Requirements

---

### Primary Area of Interest:

- Adult patients ( $\geq 18$  years) with severe atopic dermatitis (AD) receiving on-label treatment with abrocitinib, 200 mg or 100 mg, in accordance with Italian clinical practice.

### Specific Area of Interest for this RFP:

This RFP is aimed at funding mono/multicentre observational (retrospective and prospective) projects designed to collect RWD in AD in relation to one or more of the following topics:

- Abrocitinib effectiveness and safety in specific AD phenotypes (e.g. head-neck AD, itch dominant AD, AD with involvement of visible/sensitive/difficult-to-treat areas)
- Abrocitinib effectiveness related to specific outcome measure (e.g. itch, sleep, flares, pain) possibly assessed by innovative validated tools (i.e. app, questionnaire)
- Definition of standardized clinical criteria for therapeutic switch in moderate to severe AD

The overarching objective of this RFP is to support the comprehensive collection and analysis of RWD derived from the on-label administration of abrocitinib 200 mg and 100 mg in the Italian clinical practice, including:

- Dose-optimization strategies (e.g., up-titration, dose reduction, intermittent dosing)
- Long-term maintenance of therapeutic response
- Overall contextualization of the benefit-risk profile in routine clinical settings

Applicants are expected to propose research design and methodologies, including validated innovative tools, that ensure robust data capture and interpretation, contributing to a deeper understanding of abrocitinib clinical utility in the real-world scenario.

It is expected that projects will be evidence-based and follow generally accepted scientific principles. During the project review, the intended outcome of each project will be carefully evaluated, and research projects with higher likelihood to impact future patients' care will be given priority.

It is not the intent of the RFP to support off-label use of abrocitinib or to explore its efficacy and safety in not approved conditions. Accordingly, interventional studies (read as projects proposing to evaluate abrocitinib in off-label indications) will not be funded.

### Expected Approximate Monetary Range of Grant Applications

**IMPORTANT:** Grants will be distributed following a fully executed agreement and submission of Final Protocol, Documentation of IRB/IEC Approval, Regulatory Approval (if applicable), Exemption or Waiver.

- Individual projects requesting up to **50.000,00 EUR** will be considered. The estimated total available budget related to this RFP is **200.000,00 EUR**.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel's evaluation of the proposal and costs involved, and will be stated clearly in the grant agreement.

### Key Dates:



**IMPORTANT:** Be advised applications submitted after the due date will not be reviewed.

\*Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5)

### How to Submit:

**IMPORTANT:** Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to <https://www.cybergrants.com/pfizer/Research> and sign in.
  - Note: there are individual portals for each grant application type. Please be sure to use the URL above.
  - First-time users should click "Create your password".

- Click the “**Start A New Research Grant Application**” button.
- Requirements for submission:
  - Complete all required sections of the online application
  - **IMPORTANT: Upload proposal (see Appendix) in the Proposal/Protocol field.**
- In the application:
  - For the question “**Competitive Grant?**” select “**Yes**”
  - Select the following Primary Area of Interest: **Inflammation & Immunology**
- Select the following Competitive Grant Program Name: **2025 I&I Italy Dermatology RES**

### Questions:

- If you encounter any technical difficulties with the website, please click [here](#) or the “Technical Questions” link at the bottom of the page in cybergrants.
- Please click [here](#) to view “Frequently Asked Questions” regarding the Competitive Grant Program.
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Nicola Fenderico (Nicola.Fenderico@Pfizer.com), with the subject line “**2025 I&I Italy Dermatology RES – 15 Dec 2025**”

### Review and Approval Process

- Grant requests received in response to a specific RFP are reviewed by an expert review panel (ERP) to make final grant decisions.
- The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement.

### Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

### Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.

### References

1. Wollenberg A, et al. European Guideline (EuroGuiDerm) on atopic eczema: Living update. J Eur Acad Dermatol Venereol. 2025 Sep;39(9):1537-1566. doi: 10.1111/jdv.20639. Epub 2025 May 2. PMID: 40317496; PMCID: PMC12376260.
2. Gargiulo L, et al. A. Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis). J Dermatolog Treat. 2024 Dec;35(1):2411855. doi: 10.1080/09546634.2024.2411855. Epub 2024 Oct 10. PMID: 39389612..

3. Rossi M, et al. JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis). *Dermatol Ther (Heidelb)*. 2025 Oct;15(10):2833-2851. doi: 10.1007/s13555-025-01477-0. Epub 2025 Jul 24. PMID: 40705211; PMCID: PMC12454714
4. Ibba L, et al. Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study. *J Clin Med*. 2025 Apr 24;14(9):2953. doi: 10.3390/jcm14092953. PMID: 40363984; PMCID: PMC12072195.

## About Pfizer Grants

Pfizer supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

## Appendix

---

### IMPORTANT: RFP Submission Requirements

Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Full Proposal please ensure it addresses the following sections:

#### Goals and Objectives

- Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective.

#### Assessment of Need for the Project

- This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question.

#### Target Audience

- Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population.
- Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

#### Project Design and Methods

- Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan.

#### Innovation

- Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.

#### Evaluation and Outcomes

- Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures.
- Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals.

#### Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.
- An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

#### Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.
- Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant's career.

#### Organization Detail

- This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and "other"]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project.

#### Budget Detail

- The budget amount requested must be in Euro (EUR).

- While estimating your budget please keep the following items in mind:
- General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.
- The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
- Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
- It should be noted that grants awarded through GMGP cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details.

### Required Documents

- Project Plan or Proposal
- Initial Study Protocol